Cue Biopharma prices USD 30 million PIPE private placement of unregistered warrants
PUBT · 8h ago
Share
Listen to the news
- Cue Biopharma entered securities purchase agreement for $30 million PIPE financing, expected to close around May 4, 2026.
- Deal includes pre-funded warrants for up to 2,727,272 shares at effective price of $11 per pre-funded warrant with accompanying warrant.
- Financing also includes common stock warrants for up to 1,363,636 shares with $11 exercise price.
- Proceeds earmarked to advance clinical pipeline, including acquisition and development of Ascendant-221.
- Securities sold in PIPE are unregistered; Cue plans to file SEC registration statement for resale of shares issuable on warrant exercises.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved